Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Prakash Raman
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:collaboratesWith |
gptkb:Pfizer
gptkb:Novartis_Venture_Fund gptkb:Deerfield_Management |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
novel small molecule therapeutics
|
| gptkbp:focusesOn |
targeted cancer therapies
PARP inhibitors |
| gptkbp:foundedYear |
2015
|
| gptkbp:fundedBy |
venture capital
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ribon Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:program |
RBN-2397
|
| gptkbp:RBN-2397Target |
PARP7
|
| gptkbp:specializesIn |
NAD+-utilizing enzyme inhibitors
|
| gptkbp:therapeuticArea |
immunology
oncology |
| gptkbp:website |
https://ribontx.com/
|
| gptkbp:bfsParent |
gptkb:Fine_Structure_Ventures
|
| gptkbp:bfsLayer |
7
|